Jan 9, 2023 7:00 am EST Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website
Jan 3, 2023 7:01 am EST Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023
Nov 18, 2022 8:30 am EST Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants
Nov 17, 2022 6:45 am EST Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosa
Nov 9, 2022 6:45 am EST Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End
Oct 17, 2022 8:00 am EDT Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease
Sep 28, 2022 9:28 am EDT Battling Blindness: Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held Oct 19; Panelists include Kiora Pharmaceuticals, Foundation Fighting Blindness, and Retinal Surgeon Christine Kay, M.D.
Sep 15, 2022 12:23 pm EDT Kiora Pharmaceuticals To Participate in the Ladenburg Thalmann 2022 Healthcare Conference